FindTrial
Sign In

Diagnostic Study of Trans-Superior Vena Cava Mediastinal Biopsy in Superior Vena Cava Syndrome Caused by Mediastinal Space-Occupying Lesion

Diagnostic study of superior vena cava mediastinal biopsy in superior vena cava syndrome caused by mediastinal space-occupying lesion

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600127801
Enrollment
Unknown
Registered
2026-07-07
Start date
2026-07-13
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Superior Vena Cava Syndrome (SVCS) caused by mediastinal space-occupying lesions

Interventions

Treatment group:Superior vena cava mediastinal biopsy (TSVMB)

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >=18 years old; 2. Imaging confirmed mediastinal space-occupying lesions accompanied by compression or obstruction of the superior vena cava; 3. The nature of mediastinal space-occupying lesions is unknown and requires pathological diagnosis through biopsy. 4. The patient cannot tolerate other biopsy methods (including EBUS-TBNA, CT-guided puncture, mediastinoscopy biopsy, etc.) due to their own conditions, anatomical location, technical limitations, risks of general anesthesia, etc. 5. With full informed consent and the signing of the informed consent form; 6. Those with objective indicators indicating a high risk of anesthesia or those who have been assessed by two senior anesthesiologists as having an excessively high risk of general anesthesia and are not suitable for it.

Exclusion criteria

Exclusion criteria: 1.Severe cardiopulmonary dysfunction and severe coagulation dysfunction (INR >1.5 or platelet count <50 ×10^9/L); 2. There is infection in the puncture path and no obvious vascular access available for TSVMB operation; 3. Severe allergy to contrast agents or local anesthetic drugs and unable to be pre-treated; 4. End-stage disease or life expectancy less than 3 months, even if the biopsy shows that the pathology cannot change the prognosis; 5. Pregnant or lactating women; 6. Situations that other researchers consider unsuitable for enrollment.

Design outcomes

Primary

MeasureTime frame
Rate of No Immediate Severe Complications Within 30 Minutes After TSVC-MB Biopsy;—

Secondary

MeasureTime frame
The success rate of TSVC-MB biopsy (Obtaining a diagnostically positive specimen);Clarify the diagnosis time;The changes in postoperative treatment decisions;Comparison with other biopsy methods;—

Countries

China

Contacts

Public ContactJiang Faming

West China Hospital, Sichuan University

jiangfam@163.com+86 28 85422376

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026